Inhibitor Therapeutics (INTI) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free INTI Stock Alerts $0.09 +0.03 (+53.76%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineHDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsightfinance.yahoo.com - April 24 at 2:12 PMEGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsightfinance.yahoo.com - April 22 at 1:32 PMCyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth Prospectsfinance.yahoo.com - April 15 at 7:17 PMSaruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialmsn.com - April 8 at 1:55 PMWatchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applicationsfinance.yahoo.com - April 3 at 10:35 PMJanus Kinase (JAK) Inhibitor Market Forecast 2024-2034: Analyzes Trends Likely to Shape Future Opportunitiesfinance.yahoo.com - March 14 at 7:09 AMExploring the FcRn Inhibitor Market Landscape, 2024: Market Insights, Pipeline Analysis, Expert Perspectives, and Future Trends to 2034finance.yahoo.com - March 14 at 7:09 AMiTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watchseekingalpha.com - January 10 at 1:23 PMVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligotmcnet.com - January 10 at 8:23 AMIntroducing Inhibitor Therapeutics, Inc. New Scientific Advisory Boardfinance.yahoo.com - December 19 at 2:13 PMInhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins Universityfinance.yahoo.com - December 13 at 5:54 PMInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Protmcnet.com - December 4 at 10:27 AMInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activitymarkets.businessinsider.com - November 14 at 8:41 PMCardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023finance.yahoo.com - November 7 at 8:13 AMAntiverse and GlobalBio, Inc. Extend Collaboration to Advance Antibody Cancer Therapeuticsbusinesswire.com - October 16 at 4:28 PMNykode Therapeutics Announces FDA Approval of IND for VB-C-04, a Trial of VB10.16 in HPV16-Positive Cervical Cancerbenzinga.com - September 5 at 3:06 AMTrueline Therapeutics Inc.: Trueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810finanznachrichten.de - May 18 at 6:13 PMTrueline Therapeutics Announces Completion of IND-Enabling Studies for MCL1 Inhibitor TTX-810businesswire.com - May 18 at 6:13 PMCorrosion Inhibitor for Oil and Gas Market | Worldwide Industry Trends 2023-2030marketwatch.com - May 17 at 12:28 AMWax Inhibitor Market 2023 Fastest Growing Industry in Advanced Material Market by 2030marketwatch.com - May 17 at 12:28 AMInhibitor Therapeutics Inc.wsj.com - April 20 at 9:01 PMOncternal Therapeutics Announces Strategic Reprioritization, Stops Two Zilovertamab Studiesmsn.com - April 4 at 6:21 PMiOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trialuk.finance.yahoo.com - April 4 at 8:02 AM2023-2029 Medical FLT3 Inhibitor Market Share and Growth Insights | Latest Research Reportmarketwatch.com - March 31 at 8:37 AMNorepinephrine Reuptake Inhibitor Market Share by 2031marketwatch.com - March 25 at 3:53 AMProton Pump Inhibitor Drug Market with Latest Technology Estimate up to 2030marketwatch.com - March 24 at 10:15 PMPAA Scale Inhibitor Market Top Players By 2031marketwatch.com - March 24 at 7:13 AMInhibitor Therapeutics, Inc. (INTI)finance.yahoo.com - February 10 at 2:02 PMAbbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）finance.yahoo.com - January 31 at 10:29 PMQuince Therapeutics Shares Jump 65% After Sale of Protease Inhibitor Portfoliomarketwatch.com - January 29 at 11:54 AMRakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summityahoo.com - January 27 at 12:29 AMAnaplastic Lymphoma Kinase ALK Inhibitor Market Market Size 2023 Industry Analysis, Key Players, Regional Demand, Opportunity and Forecast 2028marketwatch.com - January 24 at 10:46 AMNEW THERAPY TO TREAT RARE GASTROINTESTINAL STROMAL TUMOUR APPROVED FOR NEW ZEALAND PATIENTSbenzinga.com - January 19 at 1:30 PMWax Inhibitor Market 2022 Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2028marketwatch.com - August 26 at 8:40 AMInhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemiamarkets.businessinsider.com - August 26 at 8:40 AMKinase Inhibitor Market Growth Trends and Size Analysis 2022 Segment by Regions, Dynamics, Sales revenue and Industry Share Forecast to 2030marketwatch.com - August 26 at 3:40 AMVanadium Inhibitor Market Forecast With Trends, Challenges & Drivers & Top Key Players By 2029| Exclusive 104 Pages Reportmarketwatch.com - August 19 at 3:50 PMEnzyme Inhibitor Market Share 2022 Global Business Growth, Industry Revenue, Demand and Applications Market Research Report to 2028marketwatch.com - August 16 at 6:22 AMInhibikase Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activityyahoo.com - August 12 at 7:36 PMArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Canceruk.finance.yahoo.com - August 10 at 6:04 PMArtios initiates Phase 2 study of Pol? Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancertmcnet.com - August 10 at 1:04 PMGlobal Immune Anti-Inhibitor Market 2022 Advance Technology, Latest Trend and Future Expansion by 2028marketwatch.com - August 9 at 8:45 AMeFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officerapnews.com - August 8 at 5:42 PMWeek In Review: Innovent Lands $305 Million Investment From Sanofi; Will Partner Two Candidates In Chinaseekingalpha.com - August 7 at 2:01 PMGlobal CD47 Inhibitor Drug Clinical Trials Insight 2028nz.finance.yahoo.com - August 4 at 8:46 AMPickling Inhibitor Market Trends In 2022 : Growth, Size, Segmentation, Future Demands, Latest Innovation, Sales Revenue by Regional Forecast 2028marketwatch.com - August 2 at 11:00 AMArbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitorfinance.yahoo.com - July 20 at 6:35 PMGlobal Anaplastic Lymphoma Kinase Inhibitors Market Reliable Business Data Analysis and Forecast by 2028marketwatch.com - July 19 at 7:16 AMIRLAB Expands Phase IIb/III PD-LIDs Study with Mesdopetam to Support Phase III Program and Expects Completion of Enrollment During the Summeryahoo.com - July 11 at 3:07 AMKRAS G12C Inhibitor Lumakras Sotorasib Drug Sales Forecast USD 1 Billion By 2028nz.finance.yahoo.com - July 7 at 7:29 AM Get Inhibitor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… INTI Media Mentions By Week INTI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INTI News Sentiment▼-0.150.43▲Average Medical News Sentiment INTI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INTI Articles This Week▼20▲INTI Articles Average Week Get Inhibitor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Clever Leaves News Today Lixte Biotechnology News Today ASLAN Pharmaceuticals News Today Immune Therapeutics News Today Pulmatrix News Today BetterLife Pharma News Today Pasithea Therapeutics News Today Medicure News Today TFF Pharmaceuticals News Today Theriva Biologics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:INTI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibitor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
